ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Alprazolam

Also written as “Alprazolam Extended-Release 3 mg Tablets”, “Staccato alprazolam” and “alprazolam XR”.

Its studies are mostly in Anxiety Disorders · Panic Disorder · Seizures · Epilepsy · Asthma, led by 6 companies.

Drug pageAlprazolam: every studyMany companies study it; this page follows only the 26 they lead. All 62 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 5, 200826 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris120 open or runningphase 4since Mar 5, 2008Oct 26, 2005none ahead
Teva Pharmaceutical Industriesits history only60 open or runningphase 1since Jan 26, 2009Jan 26, 2009none ahead
GlaxoSmithKlineits history only30 open or runningphase 1since Nov 28, 2012Nov 28, 2012none ahead
Novartisits history only20 open or runningphase 1since Jun 2, 2009Jun 2, 2009none ahead
Orion Corporation, Orion Pharmaits history only20 open or runningphase 1since Apr 8, 2009Apr 8, 2009none ahead
Nova Pneumaits history only10 open or runningphase 1since Jan 17, 2008Jan 17, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2005First study: phase 2 study in Dental AnxietyFirst studyNCT00245609 · 90 enrolled · Germany, United Kingdom
  2. Mar 5, 20083 phase 4 studies in Panic DisorderNCT00635531, NCT00635076, NCT00634790
  3. Mar 28, 20083 phase 1 studies in HealthyNCT00647894, NCT00650299, NCT00647634
  4. Dec 16, 2008Phase 1 study in PharmacokineticsNCT00810316 · 24 enrolled · Mexico
  5. Mar 10, 2009Phase 1 study in HealthyNCT00860119 · 23 enrolled · India
  6. Jan 7, 2010Phase 1 study in HealthyNCT01046162
  7. Apr 5, 2011Phase 1 study in Healthy SubjectsNCT01330472 · 16 enrolled · Singapore
  8. Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersNCT07777965 · 44 enrolled · United States

TargetBeta

“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule

Other programs on the same 16 targets

ProgramCompanyFurthest phaseStudies
MidazolamruleEli Lillyphase 497
ciprofolruleHaisco Pharmaceutical Groupphase 436
brexanoloneruleSupernus Pharmaceuticalsphase 414
DiazepamruleAcorda Therapeuticsphase 39

Studies

All 12 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States4CompletedAug 31, 202644
NCT01330472Healthy Subjects · Singapore1CompletedJun 201116
NCT01046162Healthy1WithdrawnJul 22, 20100
NCT00860119Healthy · India1CompletedOct 200923
NCT00810316Pharmacokinetics · Mexico1CompletedNov 200824
NCT00650299Healthy · United States1CompletedAug 200421
NCT00647634Healthy · United States1CompletedAug 200421
NCT00647894Healthy · United States1CompletedJan 200524
NCT00635531Panic Disorder · United States4Terminated16
NCT00635076Panic Disorder · United States4Terminated3
NCT00634790Panic Disorder · United States4Terminated49
NCT00245609Dental Anxiety · Germany, United Kingdom2Completed90

How it is read

Names in the registry

  • “Alprazolam”, 10 entries
  • “Alprazolam Extended-Release 3 mg Tablets”, 4 entries
  • “Staccato alprazolam”, 3 entries
  • “alprazolam XR”, 3 entries
  • “Staccato Alprazolam”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.